Follow Louisiana Illuminator on Facebook and X.

Current and resolved drug shortages and discontinuations reported to FDA, Food and Drug Administration (2024) Bydureon BCise highlights of prescribing information, Food and Drug Administration (2022) Ozempic highlights of prescribing information, Food and Drug Administration (2023) Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with Type 2 diabetes (Sustain 3): A 56-week, open-label, randomized clinical trial, Diabetes Care (2018) Label: Bydureon BCise, DailyMed (2023) Label: Ozempic, Daily Med (2023) GLP-1 receptor agonists and the risk of thyroid cancer, Diabetes Care (2023) Drug-drug interactions between glucagon-like peptide 1 receptor agonists and oral medications: A systematic review, Drug Safety (2024) The clinical efficacy and safety of glucagon-like peptide-1 (GLP-1) Agonists in adults with Type 2 diabetes mellitus, Clinical Medicine Insights: Endocrinology and Diabetes (2011) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice

As compared to Victoza (liraglutide), Ozempic has a three-fold lower attraction for the bodys GLP-1 receptor, but a much longer half-life
Its commonly prescribed off-label for weight loss, and theres another medication called Wegovy, which contains the same active ingredient, semaglutide, and is FDA-approved for chronic weight management